Collectively, these findings establish SLC39A14-PIWIL2 as a novel oncogenic fusion in HCC and highlight fusion protein–targeted peptide therapeutics as a promising avenue for precision treatment in HCC. Here, PIWIL2 is linked to hepatocellular carcinoma.